The considerable need for research on Alzheimer disease (AD) is complicated by the impaired capacity of patients with AD to provide informed consent to participate in research and the lack of well-defined policy guidelines on this issue. Scott Kim highlights the importance of distinguishing between capacity and authenticity when assessing the ability of a patient with AD to provide informed consent, and discusses how the role of surrogate decision-makers could be enhanced in this context.